EMA Publishes Framework and Action Plan for Closer Interaction with the Academic Community
Collaboration with academia to be reinforced
- Date: 05 Apr 2017
- Topic: Bioethics, legal and economic issues
As a science-driven organisation, the European Medicines Agency (EMA) announced on 3 April 2017 that it has developed a framework to formalise, structure and further develop interactions with the academic community in the context of the European medicines regulatory network.
The framework and an action plan for the next three-years were adopted by EMA’s Management Board at its March 2017 meeting.
“Academia play an important role in helping the EU medicines regulatory network keep abreast of the opportunities and challenges brought by science, be it in the context of the development, assessment or safety monitoring of medicines, says EMA’s Executive Director Guido Rasi. “The framework will allow us to integrate cutting-edge scientific knowledge more tightly into our activities. It will also help academic start-ups benefit from advice from the EU regulatory network to translate their discoveries into patient-focused medicines.”
In accompanied press release EMA has also published reflections from different academia representatives from which we highlight the quote from Dr Rosa Giuliani from the ESMO EU Policy Committee and ESMO representative within the EMA Healthcare Professionals Working Party (HCPWP), as well as the co-chair of the EMA- Academia topic group within the HCPWP.
“The dialogue between EMA and academia has already improved in time. However, this is the perfect moment to structure this interaction and bring it to the next level. The framework of collaboration is a timely initiative, which is expected to fulfil specific tasks. This is the platform needed to 1) promote regulatory awareness, 2) support academic research and 3) boost communication between the two parties. Now it is time to work!”
Dr Rosa Giuliani, EU Policy Committee, European Society for Medical Oncology (ESMO)
The framework’s overall objectives are:
- raising awareness of the mandate and work of the European medicines regulatory network to increase academia’s trust in and engagement with the regulatory system;
- fostering the translation of academic research into novel methodologies and medicines which meet regulatory standards and address needs of public and animal health;
- ensuring that the best scientific expertise and academic research are available on time to support effective evidence generation, regulatory advice and guidance, as well as decision-making in regulatory processes;
- working with academia to develop regulatory science that embraces scientific progress in medicines development without compromising patient safety, such as for example, the use of novel endpoints or novel methodologies.
The framework builds on EMA’s experience in interacting with stakeholder associations representing patients and consumers, healthcare professionals and the pharmaceutical industry, which is based on the fundamental principles of transparency, independence and integrity, accountability, and broad representation.
Along with the framework, EMA has developed an action plan which includes, among other activities, initiatives for mutual education and training, staff exchange programmes to promote mutual learning, a strategic research agenda for regulatory science and the creation of an EMA entry point for academia to receive information on available support within the EU Regulatory Network.
EMA also published a new web page for academia providing links to content that is likely to be of interest, and a section describing the way EMA interacts with academia, with more detail on the collaboration framework and action plan and useful resources for academics.